CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The project aims to improve cancer immunotherapy by targeting specific carbohydrate structures on tumor cells. By using chimeric antigen receptor T cell technology, it seeks to enhance the specificity and safety of treatments for various carcinomas, addressing limitations of current therapies.
Major limitations in current immunotherapy success are low antigenicity of targeting antigen and tumor heterogeneity.
Hence there is an unmet need for novel antigen targets that could potentially be expressed on many tumor types.
Cancer express aberrant cell surface glycosylation patterns compared to normal cells.
These tumor-associated carbohydrate-neoantigens can be targeted for tumor cell killing by antibodies and cytotoxic immune cells.
Sialic acids cover cell surface glycans and frequently…
TEL AVIV UNIVERSITY
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
